Michael Kongnyuy1, Abhinav Sidana1, Arvin K George1, Akhil Muthigi1, Amogh Iyer1, Michele Fascelli1, Meet Kadakia1, Thomas P Frye1, Richard Ho1, Francesca Mertan2, M Minhaj Siddiqui3, Daniel Su1, Maria J Merino4, Baris Turkbey2, Peter L Choyke2, Bradford J Wood5, Peter A Pinto6. 1. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD. 2. Molecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, MD. 3. Department of Urology, University of Maryland Medical School, Baltimore, MD. 4. Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD. 5. Center for Interventional Oncology, National Cancer Institute & NIH Clinical Center, National Institutes of Health, Bethesda, MD. 6. Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address: pintop@mail.nih.gov.
Abstract
INTRODUCTION: African-American (AA) men tend to harbor high-risk prostate cancer (PCa) and exhibit worse outcomes when compared to other groups. It has been postulated that AA men may harbor more anterior prostate lesions (APLs) that are undersampled by the standard transrectal ultrasound guided-biopsy (SBx), potentially resulting in greater degree of Gleason score (GS) upgrading at radical prostatectomy. We aimed to evaluate the detection rate of anterior PCa significance of APLs in AA men on multiparametric magnetic resonance imaging (mpMRI) and compare it to a matched cohort of White/Other (W/O) men. MATERIALS AND METHODS: A review of 1,267 men who had an mpMRI with suspicious prostate lesions and who underwent magnetic resonance transrectal ultrasound fusion-guided biopsy (FBx) with concurrent SBx in the same biopsy session was performed. All AA men were matched to a control group of W/O using a 1:1 propensity score-matching algorithm with age, prostate-specific antigen, and prostate volume as matching variables. Logistic regression analysis was used to determine predictors of APLs in AA men. RESULTS: Of the 195 AA men who underwent mpMRI, 93 (47.7%) men had a total of 109 APLs. Prior negative SBx was associated with the presence of APLs in AA men (Odds ratio = 1.81; 95% CI: 1.03-3.20; P = 0.04). On multivariate logistic regression analysis, smaller prostate (P = 0.001) and rising prostate-specific antigen (P = 0.007) were independent predictors of cancer-positive APLs in AA men. Comparative analysis of AA (93/195, 47.7%) vs. W/O (100/194, 52%) showed no difference in the rates of APLs (P = 0.44) or in cancer detection rate within those lesions or the distribution of GS within those cancers (P = 0.63) despite an overall higher cancer detection rate in AA men (AA: 124/195 [63.6%] vs. W/O: 97/194 [50.0%], P = 0.007). In cases where APLs were positive for PCa on FBx, the GS of APL was equal to the highest GS of the entire gland in 82.9% (29/35) and 90.9% (30/33) of the time in AA and W/O men, respectively. CONCLUSION: Cancer-positive APLs represented the highest risk GS in most cases. AA men with prior negative SBx are twice as likely to harbor a concerning APL. In our cohort, AA and W/O men had comparable rates of APLs on mpMRI. Thus, differences in APLs do not explain the higher risk of AA men for deahth due to PCa. However, targeting of APLs via FBx can clinically improve PCa risk stratification and guide appropriate treatment options.
INTRODUCTION: African-American (AA) men tend to harbor high-risk prostate cancer (PCa) and exhibit worse outcomes when compared to other groups. It has been postulated that AA men may harbor more anterior prostate lesions (APLs) that are undersampled by the standard transrectal ultrasound guided-biopsy (SBx), potentially resulting in greater degree of Gleason score (GS) upgrading at radical prostatectomy. We aimed to evaluate the detection rate of anterior PCa significance of APLs in AA men on multiparametric magnetic resonance imaging (mpMRI) and compare it to a matched cohort of White/Other (W/O) men. MATERIALS AND METHODS: A review of 1,267 men who had an mpMRI with suspicious prostate lesions and who underwent magnetic resonance transrectal ultrasound fusion-guided biopsy (FBx) with concurrent SBx in the same biopsy session was performed. All AA men were matched to a control group of W/O using a 1:1 propensity score-matching algorithm with age, prostate-specific antigen, and prostate volume as matching variables. Logistic regression analysis was used to determine predictors of APLs in AA men. RESULTS: Of the 195 AA men who underwent mpMRI, 93 (47.7%) men had a total of 109 APLs. Prior negative SBx was associated with the presence of APLs in AA men (Odds ratio = 1.81; 95% CI: 1.03-3.20; P = 0.04). On multivariate logistic regression analysis, smaller prostate (P = 0.001) and rising prostate-specific antigen (P = 0.007) were independent predictors of cancer-positive APLs in AA men. Comparative analysis of AA (93/195, 47.7%) vs. W/O (100/194, 52%) showed no difference in the rates of APLs (P = 0.44) or in cancer detection rate within those lesions or the distribution of GS within those cancers (P = 0.63) despite an overall higher cancer detection rate in AA men (AA: 124/195 [63.6%] vs. W/O: 97/194 [50.0%], P = 0.007). In cases where APLs were positive for PCa on FBx, the GS of APL was equal to the highest GS of the entire gland in 82.9% (29/35) and 90.9% (30/33) of the time in AA and W/O men, respectively. CONCLUSION:Cancer-positive APLs represented the highest risk GS in most cases. AA men with prior negative SBx are twice as likely to harbor a concerning APL. In our cohort, AA and W/O men had comparable rates of APLs on mpMRI. Thus, differences in APLs do not explain the higher risk of AA men for deahth due to PCa. However, targeting of APLs via FBx can clinically improve PCa risk stratification and guide appropriate treatment options.
Authors: Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster Journal: N Engl J Med Date: 2010-04-01 Impact factor: 91.245
Authors: Nabeel A Shakir; Arvin K George; M Minhaj Siddiqui; Jason T Rothwax; Soroush Rais-Bahrami; Lambros Stamatakis; Daniel Su; Chinonyerem Okoro; Dima Raskolnikov; Annerleim Walton-Diaz; Richard Simon; Baris Turkbey; Peter L Choyke; Maria J Merino; Bradford J Wood; Peter A Pinto Journal: J Urol Date: 2014-08-09 Impact factor: 7.450
Authors: Baris Turkbey; Vijay P Shah; Yuxi Pang; Marcelino Bernardo; Sheng Xu; Jochen Kruecker; Julia Locklin; Angelo A Baccala; Ardeshir R Rastinehad; Maria J Merino; Joanna H Shih; Bradford J Wood; Peter A Pinto; Peter L Choyke Journal: Radiology Date: 2010-12-21 Impact factor: 11.105
Authors: Ghazi Al Edwan; Sangeet Ghai; David Margel; Girish Kulkarni; Rob Hamilton; Ants Toi; Masoom A Haidar; Antonio Finelli; Neil E Fleshner Journal: Can Urol Assoc J Date: 2015 May-Jun Impact factor: 1.862
Authors: M R Abern; M R Bassett; M Tsivian; L L Bañez; T J Polascik; M N Ferrandino; C N Robertson; S J Freedland; J W Moul Journal: Prostate Cancer Prostatic Dis Date: 2012-10-16 Impact factor: 5.554
Authors: Frederico R Romero; Antonio W Romero; Rui Manuel S de Almeida; Renato Tambara Filho Journal: Int Braz J Urol Date: 2012 Jul-Aug Impact factor: 1.541
Authors: M Kongnyuy; M M Siddiqui; A K George; A Muthigi; A Sidana; M Maruf; B Turkbey; P L Choyke; B J Wood; P A Pinto Journal: Prostate Cancer Prostatic Dis Date: 2017-04-25 Impact factor: 5.554
Authors: Matthew J Watson; Arvin K George; Mahir Maruf; Thomas P Frye; Akhil Muthigi; Michael Kongnyuy; Subin G Valayil; Peter A Pinto Journal: Future Oncol Date: 2016-07-12 Impact factor: 3.404
Authors: Akhil Muthigi; Abhinav Sidana; Arvin K George; Michael Kongnyuy; Nabeel Shakir; Meet Kadakia; Mahir Maruf; Thomas P Frye; Francesca Mertan; Daniel Su; Maria J Merino; Peter L Choyke; Baris Turkbey; Bradford J Wood; Peter A Pinto Journal: Int Urol Nephrol Date: 2016-06-15 Impact factor: 2.370
Authors: Ariel A Schulman; Christina Sze; Efrat Tsivian; Rajan T Gupta; Judd W Moul; Thomas J Polascik Journal: Curr Urol Rep Date: 2017-07 Impact factor: 3.092
Authors: Arvin K George; Baris Turkbey; Subin G Valayil; Akhil Muthigi; Francesca Mertan; Michael Kongnyuy; Peter A Pinto Journal: Abdom Radiol (NY) Date: 2016-05
Authors: B Calio; A Sidana; D Sugano; S Gaur; A Jain; M Maruf; S Xu; P Yan; J Kruecker; M Merino; P Choyke; B Turkbey; B Wood; P Pinto Journal: Prostate Cancer Prostatic Dis Date: 2017-08-01 Impact factor: 5.554
Authors: Kosj Yamoah; Priti Lal; Shivanshu Awasthi; Arash O Naghavi; Robert J Rounbehler; Travis Gerke; Anders E Berglund; Julio M Pow-Sang; Edward M Schaeffer; Jasreman Dhillon; Jong Y Park; Timothy R Rebbeck Journal: Prostate Date: 2020-11-03 Impact factor: 4.104